A positive PET scan in the lung does not automatically mean cancer. PET scans detect areas of high metabolic activity by tracking how cells absorb a sugar-based tracer, and many non-cancerous conditions rev up cellular metabolism enough to light up on the image. Infections, inflammatory diseases, benign tumors, post-treatment scarring, and even recent vaccinations can all produce a “hot spot” that looks worryingly similar to lung cancer. Understanding why false positives happen, and how often, can spare you a lot of unnecessary panic between the scan and the biopsy results.
How PET Scans Work and Why They Overreact
PET scans used in lung cancer evaluation rely on a radioactive glucose tracer. Cancer cells tend to be metabolic gluttons, burning through glucose far faster than normal tissue, so they absorb more of the tracer and glow brighter on the image. Radiologists use a measurement called SUVmax to quantify how intensely a spot lights up. An SUVmax above 2.5 has traditionally been treated as the threshold suggesting malignancy. But here is the problem: cancer cells are not the only ones that consume glucose at high rates. Any cell that is actively dividing, fighting infection, or involved in inflammation can do the same thing. That overlap is where false positives come from.
The specificity of PET scans for lung nodules varies quite a bit depending on the clinical setting. One study found that when the standard SUVmax cutoff of 2.5 was used for nodules of different sizes, specificity ranged from as low as 17% for nodules larger than 3 cm to 47% for nodules between 1 and 2 cm.1PubMed Central. Relation between nodule size and 18F-FDG-PET SUV for malignant and benign pulmonary nodules In other words, a significant fraction of “positive” scans turn out to be something other than cancer, and the rate of false alarms depends heavily on the size of the nodule and the patient’s background.
Fungal Infections, Especially Histoplasmosis
If you live in certain parts of the world, a fungal infection is one of the most common reasons a PET scan lights up without cancer being present. Histoplasmosis, caused by a soil fungus found throughout the Ohio and Mississippi River valleys in the United States and in parts of Central America, creates granulomas in the lungs. These granulomas are clusters of immune cells walling off the infection, and they burn glucose at rates that easily cross the malignancy threshold on PET. A study from a high-histoplasmosis region found that while PET was 93% sensitive for detecting actual lung cancer, its specificity dropped to just 40%, meaning that more than half of benign nodules were falsely flagged as suspicious.2PubMed. FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence
This geographic effect is not limited to histoplasmosis. A meta-analysis published in JAMA found that PET specificity for lung cancer was about 16 percentage points lower in regions where infectious lung disease is common compared to regions where it is not, averaging roughly 61% versus 77%.3PubMed Central. Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: A meta-analysis Sensitivity, the scan’s ability to catch actual cancer, stayed about the same regardless of location. So the scan remains good at not missing cancer, but in infection-prone areas it rings a lot more false alarms.
Tuberculosis Mimicking Lung Cancer
Tuberculosis is a particularly sneaky mimic. Active TB lesions in the lung can appear as masses or nodules on CT, and because TB triggers a vigorous immune response, SUVmax values routinely exceed the 2.5 threshold. In a retrospective study comparing TB patients to lung cancer patients, every single one of the 36 TB cases had an SUVmax above 2.5, with an average around 6.0.4PubMed Central. Asymptomatic pulmonary tuberculosis mimicking lung cancer on imaging: A retrospective study Lung cancer patients in the same study averaged higher, around 10, but the overlap was substantial enough that no single scan reading could reliably tell the two apart.
The consequences of this confusion go beyond a single nodule. In a review of PET/CT cases where tuberculosis was mistaken for malignancy, TB caused false positive readings in staging scans, restaging scans, and even in patients who had no cancer at all. Four patients without any malignancy were falsely considered to have lung cancer based on PET results, and in the majority of actual cancer patients, TB led to overstaging, meaning doctors thought the cancer had spread further than it actually had.5Journal of Nuclear Medicine. F-18 FDG PET/CT findings of tuberculosis mimicking malignancy In parts of Asia, Africa, and South America where TB remains common, this is a daily diagnostic challenge.
Parasitic Infections in Endemic Regions
Hydatid cysts, caused by the tapeworm Echinococcus, are another regional false-positive trap. These cysts can form solitary pulmonary nodules that look ominous on imaging, especially in a patient with risk factors like smoking. A case report highlighted a heavy smoker with a solitary pulmonary nodule and a positive PET scan, findings that screamed lung cancer, only for the nodule to turn out to be a hydatid cyst.6PubMed Central. Can a Solitary Pulmonary Nodule With Positive PET Scan in a Heavy Smoker be Something Other Than Lung Cancer? A Case Report of Pulmonary Hydatid Cyst and Literature Review If you have traveled to or lived in areas where these parasites are endemic, including the Mediterranean, Middle East, parts of South America, and Central Asia, your doctor should factor that into how they interpret a positive PET result.
Sarcoidosis and Granulomatous Disease
Sarcoidosis is an inflammatory condition that causes clusters of immune cells called granulomas to form in various organs, most often the lungs and the lymph nodes inside the chest.7PubMed. PET/CT in the Diagnosis and Workup of Sarcoidosis: Focus on Atypical Manifestations These granulomas are metabolically active and pick up the PET tracer readily. Lung nodules, consolidations, lymph node enlargement, and even pleural thickening from sarcoidosis can all show increased tracer uptake.8PubMed Central. The role of PET in the management of sarcoidosis
The irony is that PET is actually very good at detecting sarcoidosis: a meta-analysis found a pooled sensitivity above 97% for picking up pulmonary sarcoidosis.9PubMed Central. Meta-analysis of [(18)F]FDG-PET/CT in pulmonary sarcoidosis The trouble is that the scan cannot tell you whether those bright spots are sarcoidosis or cancer without additional context. A patient who presents with bilateral hilar lymph node enlargement and lung nodules might have sarcoidosis, lymphoma, or metastatic disease, and all three can look strikingly similar on PET. Clinical history, blood tests, and often a biopsy are needed to sort it out.
Rheumatoid Nodules and Autoimmune Lung Disease
People with rheumatoid arthritis sometimes develop lung nodules as part of their disease. These rheumatoid pulmonary nodules can show up on PET with measurable tracer uptake, raising concern for cancer. One study comparing rheumatoid nodules to malignant nodules found that rheumatoid nodules tended to have lower metabolism, with an average SUVmax of about 2.7 compared to 7.2 for cancerous nodules, and they typically lacked the intensely active draining lymph nodes that cancer often shows.10PubMed. Rheumatoid pulmonary nodules: clinical and imaging features compared with malignancy Still, a rheumatoid nodule with an SUVmax near 3 or 4 sits right in the gray zone where cancer is suspected, and a biopsy is often the only way to get a definitive answer.
Organizing Pneumonia
Organizing pneumonia is a type of lung inflammation where the small airways and air sacs fill with inflammatory tissue. When it forms a focal mass rather than a diffuse pattern, it can closely mimic a lung tumor both on CT and PET. In a study of patients with organizing pneumonia that mimicked lung cancer, focal lesions had a mean SUVmax of about 6.7, well above the threshold for suspected malignancy.11PubMed Central. The Evaluation of FDG PET/CT Scan Findings in Patients with Organizing Pneumonia Mimicking Lung Cancer These lesions favored the upper lobes and sometimes showed cavitation, features also seen in certain lung cancers. The overlap is close enough that some patients end up going to surgery before the true diagnosis becomes clear.
Benign Lung Tumors
Not every tumor in the lung is malignant. Hamartomas, the most common benign lung tumor, are disorganized clumps of normal tissue, often containing cartilage and fat. They tend to show low tracer uptake on PET, with an average SUVmax around 1.5 in one study.12PubMed Central. 18F-FDG PET/CT characteristics of pulmonary sclerosing hemangioma vs. pulmonary hamartoma That is usually below the cancer-suspicion threshold, which sounds reassuring, but the picture gets complicated. Another study found that while hamartomas averaged about 1.65, there was enough variability that some crossed the 2.5 line, and carcinoid tumors, which are slow-growing cancers, averaged around 4 to 6 but could go higher.13PubMed Central. Contribution of 18F-FDG PET/CT in the Differential Diagnosis of Pulmonary Hamartomas and Pulmonary Carcinoids The clinical challenge is distinguishing a slightly active hamartoma from a lazy carcinoid when both produce modest PET signals.
Post-Treatment Changes
If you have already been treated for lung cancer with radiation therapy, PET scans become harder to interpret. Radiation pneumonitis, an inflammatory reaction in the lung tissue that was irradiated, can cause persistent tracer uptake that looks a lot like recurring cancer. A study examining PET scans after carbon-ion radiotherapy found that the standard SUVmax measurement could not reliably distinguish between cancer recurrence and radiation-induced inflammation, because both produced similar values.14Scientific Reports. Differentiation between non-small cell lung cancer and radiation pneumonitis after carbon-ion radiotherapy by 18F-FDG PET/CT texture analysis Advanced image analysis techniques looking at the texture of the uptake pattern did better at telling the two apart, but these tools are not yet widely available in standard clinical practice. This means that for patients in post-treatment surveillance, a positive PET finding requires especially careful interpretation and often a biopsy.
Metastases from Other Cancers
A positive PET finding in the lung does not necessarily mean lung cancer specifically. The lungs are a common destination for cancer cells that have spread from elsewhere in the body. Cancers of the breast, colon, kidney, thyroid, and many other organs frequently metastasize to the lungs, and those metastases light up on PET just as a primary lung cancer would. Even rare tumors can show up as lung nodules on PET; a case report described a placental-site trophoblastic tumor, an extremely uncommon gynecologic malignancy, that was detected as a persistent lung nodule on PET and required surgical removal.15PubMed. Placental-site trophoblastic tumor with PET scan-detected surgically treated lung metastasis A positive PET scan in the lung in someone with a known cancer elsewhere raises the question of metastatic disease rather than a new primary lung cancer.
Brown Fat and Technical Artifacts
Sometimes the scan lights up something that is not even a lesion. Brown adipose tissue, the type of fat your body activates to generate heat, consumes glucose at high rates and can produce bright spots on PET. This uptake is typically seen in the neck, above the collarbones, and around the large blood vessels in the chest.16PubMed Central. Causes and imaging features of false positives and false negatives on 18F-PET/CT in oncologic imaging An early study estimated that identifiable brown-fat or muscle uptake occurred in roughly 4% of patients undergoing PET, enough to be a recurring source of confusion.17Journal of Nuclear Medicine. Patterns of 18F-FDG Uptake in Adipose Tissue and Muscle: A Potential Source of False-Positives for PET Experienced radiologists can usually recognize these patterns, especially when the PET findings are cross-referenced with the CT images that are acquired simultaneously. But in borderline cases, brown fat uptake near the mediastinum or intercostal spaces could briefly raise the wrong alarm.
Vaccination-Related Lymph Node Uptake
The COVID-19 vaccination campaign introduced a new and initially unexpected source of false positives. Vaccines trigger an immune response that can cause lymph nodes near the injection site to swell and become metabolically active, producing bright spots on PET. In patients being scanned for cancer evaluation, these reactive lymph nodes were sometimes mistaken for metastatic disease. One case involved a melanoma patient whose post-vaccination axillary lymph node uptake triggered unnecessary additional imaging.18PubMed Central. Interference of COVID-19 Vaccination With PET/CT Leads to Unnecessary Additional Imaging in a Patient With Metastatic Cutaneous Melanoma-Case Report Another documented a lung cancer patient whose left axillary nodes lit up a week after an Oxford-AstraZeneca vaccination, raising concern about metastasis that turned out to be a normal immune reaction.19PubMed Central. False-Positive Axillary Lymph Nodes on FDG PET/CT Resulting From COVID-19 Immunization
In one particularly alarming case, a 66-year-old man who had been in complete remission from non-small cell lung cancer for four and a half years had a PET scan that showed new clusters of avid lymph nodes in the axilla and supraclavicular region, strongly suggesting cancer recurrence. It turned out he had received his second COVID-19 mRNA vaccine dose seven days before the scan.20Libyan Journal of Medical Sciences. COVID-19 mRNA Vaccination-induced Lymphadenopathy Mimics Lung Cancer Metastasis On Fluorodeoxyglucose PET/CT Scan The lesson here extends beyond COVID-19 vaccines. Any recent vaccination can potentially cause reactive lymphadenopathy, and your doctor should know about all vaccinations received in the weeks before a PET scan.
Why Biopsy Remains the Gold Standard
Given the long list of look-alikes, it is no surprise that a positive PET scan rarely ends the diagnostic process. Tissue biopsy, where a sample of the suspicious area is physically removed and examined under a microscope, remains the definitive way to distinguish cancer from its many mimics. A prospective study found that when doctors discussed PET/CT results in the context of each patient’s full clinical picture, the initial management plan, including whether to proceed with biopsy, was changed in about 35% of cases.21PubMed Central. Biopsy decision for intermediate–high-risk lung nodules is significantly changed when guided by prior positron emission tomography/CT (PET/CT) results: results of the prospective PET-FIRST study PET results help steer decision-making, not replace it.
Clinicians also use risk-prediction models that combine PET findings with other factors like age, smoking history, nodule size, and nodule shape to estimate the probability of cancer before deciding next steps. These models, validated across multiple centers, perform well at sorting patients into risk categories that guide whether to biopsy immediately, monitor with follow-up scans, or pursue other testing.22PubMed. Multicenter external validation of two malignancy risk prediction models in patients undergoing 18F-FDG-PET for solitary pulmonary nodule evaluation The PET result is one input in a larger equation, not the final verdict.
When the SUV Threshold Misleads
The widely used SUVmax cutoff of 2.5 deserves some skepticism. It was established as a general guideline, but it performs differently depending on nodule size, patient population, and regional disease patterns. A screening study found that when the SUVmax threshold was set at 2.5, sensitivity for detecting actual cancer dropped to just 46%, missing more than half of malignancies, while specificity reached 97%.23PubMed. Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT Lowering the threshold to 1.5 raised sensitivity to 65% but still missed about a third of cancers. There is no single number that cleanly separates cancer from everything else, which is why radiologists interpret PET findings in context rather than relying on a simple cutoff.
Emerging Tools to Reduce False Positives
Researchers are working on better ways to tell cancer from its imposters. One promising avenue is radiomics, which uses computer algorithms to analyze the texture and patterns within PET images beyond what the human eye can assess. A study that combined radiomics-based scores with traditional radiologist interpretation achieved a false positive rate as low as 5% in the training group and 9% in the test group, a substantial improvement over standard reading.24PubMed. Integrating manual diagnosis into radiomics for reducing the false positive rate of (18)F-FDG PET/CT diagnosis in patients with suspected lung cancer These hybrid approaches suggest that AI-assisted interpretation could meaningfully reduce the number of patients sent through unnecessary biopsies or surgeries.
Another direction involves developing new PET tracers that target biological processes more specific to cancer than simple glucose metabolism. Because glucose consumption is shared by so many cell types, a tracer designed to detect something cancer cells do but inflammatory cells do not, like accelerated DNA synthesis or specific receptor expression, could dramatically improve specificity. Several such tracers are under investigation, though none has yet replaced the standard glucose-based tracer in routine clinical practice. The recognition that glucose metabolism alone has real limits for distinguishing cancer from non-cancer is driving substantial research investment in alternatives.